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ABSTRACT
Background: Dermographic urticaria (DU) is characterized by strong itch and wheals induced by mechanical
scratching. H1-receptor antagonists may reduce symptoms of DU to some extent, but other treatments being
used for chronic spontaneous urticaria, such as H2-receptor antagonists and corticosteroids, are not usually ef-
fective for DU.
Case Summary: We here report six cases of antihistamine-resistant DU treated with oral ciclosporin. Four
cases suffering from severe itches that spontaneously occurred before the appearance of wheals in response
to scratching were substantially improved by use of ciclosporin for 21, 16, 32, and 8 months, and one of them
reached complete remission. Two cases did not obtain a benefit from the treatment, because of insufficient ef-
fects andor side effects.
Discussion: Oral ciclosporin may be of value as a potential treatment of anti-histamine-resistant DU.
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INTRODUCTION
Dermographic urticaria (DU), also known as ‘urti-
caria factitia’ or ‘symptomatic dermographism’, is a
subtype of physical urticaria and commonly observed
in daily clinical practices.1 It is characterized by
linear-shaped wheals that appear shortly after a
scratch or any other mechanical stimuli on the skin,
along with the area of stimuli. In most cases, patients
also suffer from severe itching together with wheals
and this thus markedly perturbs their quality of life
(QOL). In certain cases, severe itching may occur on
intact skin without apparent stimuli, followed by
wheals which are subsequently induced by scratch-
ing. DU affects mainly young adults,2,3 and mean du-
ration is reported to be 6.5 years.4
A principle of the treatment for DU and other
physical urticaria is the avoidance of responsible
physical stimuli and medications based on H1-
receptor antagonists. However, it is impractical to
completely avoid mechanical stimuli on the skin, and
H1-receptor antagonists may not be effective for many
cases of DU, as those for acute and chronic spontane-
ous urticaria even at high doses. Several other thera-
pies, including H2-receptor antagonists5 and pho-
totherapy such as narrow-band UVB6 have been re-
ported, but do not usually bring further benefit over
H1-antagonists. Moreover, corticosteroids, which
may suppress symptoms of many cases of chronic
spontaneous urticaria and delayed pressure urticaria,
are not effective for DU. Several guidelines for the
treatment of urticaria indicate oral ciclosporin (CsA)
as an option for the treatment of chronic spontaneous
urticaria, when patients do not respond to updosing
or changes of anti-histamines and the addition of a
leukotriene antagonists.7-9 So far, there is no study re-
garding the effectiveness of CsA on DU in the litera-
tures. We here report six cases of severe and
antihistamine-resistant DU who were treated with low
doses of oral CsA.
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Table　1　Clinical characteristics of the 6 patients
Patient Age, y/ Sex
Duration 
of DU, y
Starting dose of 
CsA, mg/kg/day
Duration of 
CsA, m Previous medications Outcome
Adverse 
effects
1 56/M  4 3.0 21 H1-antagonists in 3-fold doses, cor-
ticosteroids (5 mg/day, 2 weeks)
Remission None
2 67/F  3.4 16, continue H1-antagonists in 3-fold doses, leu-
kotriene antagonists, corticoste-
roids (2.5-20 mg/day,  2 years)
Improvement None
3 25/F 2.5 32, continue H1-antagonists in 3-fold doses, H2-
antagonists, leukotriene antago-
nists, corticosteroids (2.5-7.5 mg/
day, 2 years)
Improvement Epigastric 
distress
4 26/F   2.7 8, continue H1-antagonists in 3-fold doses, leu-
kotriene antagonists, corticoste-
roids (10-30 mg/day, 2 weeks)
Improvement None
5 65/F 2.0 0.5 H1-antagonists in 4-fold doses, cor-
ticosteroids (5 mg/day, 2 weeks)
Inefficiency None
6 43/M  0.8 0.25 H1-antagonists in 3-fold doses, leu-
kotriene antagonists
Inefficiency Headache, 
nausea
Abbreviations: DU, dermographic urticaria; CsA, ciclosporin. Dose of corticosteroids, converted into predonizolone.
CLINICAL SUMMARY
We treated six adult patients (two men and four
women, 25 to 67 years old) given a diagnosis of DU
on the basis of medical history and provocation test.
All patients developed wheal and flare in the inside of
the forearm being rubbed by the strength of approxi-
mately 60 gmm2.10 The other types of physical urti-
caria were excluded by the provocation test per-
formed as necessary. In cases 1 to 4, patients had
noted that severe itching with or without flare might
have occurred spontaneously before they scratched,
and developed wheals in that area. But wheals had
never developed spontaneously without scratching or
mechanical stimuli in all six cases. All patients had
been treated with H1-receptor antagonists, including
their updosing and combinations with different H1-
antagonists (Table 1). However, their symptoms had
not been sufficiently controlled, and their QOL had
been markedly impaired. All patients did not show ap-
parent blood abnormalities in complete blood counts
and routine examinations of serum biochemistry.
They thus took oral CsA (0.8 to 3.4 mgkg per day)
in addition to current treatments. Blood examinations
including serum creatinine and serum level of CsA
were performed every four weeks to monitor the oc-
currence of adverse effects. Ethic committee of the
University Hospital approved about the administra-
tion of CsA for the patients with DU.
CASE 1
A 56-year-old man had a four-year history of wheals
and itching. Despite treatment with H1-antagonists
and corticosteroids, his symptoms had not improved.
CsA was initiated at a dose of 3.0 mgkg per day in
addition to 10 mg olopatadine hydrochloride, 10 mg
loratadine and 500 mg tranexamic acid. After 2 days
of initiating treatment with CsA, he felt an apparent
improvement in his itching. The frequency of wheals
decreased gradually. One month later, the dose of
CsA was reduced to 0.75 mgkg per day, but no exac-
erbation was observed. We then tapered the dose to
0.38 mgkg per day 11 months later. At this stage, he
noted slight itching once for several days. We eventu-
ally discontinued CsA 21 months later, but his symp-
toms did not relapse. We sequentially stopped the
other medications, and he became drug-free after 27
months of treatment. No apparent side effects were
observed during the treatment. Thereafter, he has
maintained full remission without any medication
during 15 months of follow-up.
CASE 2
A 67-year-old woman had a five-year history of wheals
and itching. She developed these symptoms even
when exposed to water pressure from a shower. De-
spite treatment with H1-antagonists, leukotriene an-
tagonists and corticosteroids, her symptoms had not
apparently improved. In addition to 20 mg cetirizine
hydrochloride and 10 mg montelukast, CsA was un-
dertaken at a dose of 3.4 mgkg per day. After two
weeks, she showed an apparent improvement in her
itching. When we tapered the dose to 2.3 mgkg per
day after two months treatment with CsA, she felt her
itching worsened. We then returned the dose to 3.4
mgkg per day, and the itching decreased again.
When the dose was decreased to 2.3 mgkg per day
after seven months treatment, her itching did not
worsen. She continued to take this dose of CsA for 18
months without apparent side effects. At this stage,
rubbing skin with 60 gmm2 pressure did not develop
wheal, and the appearance of both flare and itching
was substantially reduced as compared with that be-
fore the treatment with CsA.
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CASE 3
A 25-year-old woman had a 12-year history of wheals
and itching. Despite treatment with H1 and H2-
antagonists, leukotriene antagonists and corticoster-
oids, her symptoms had not improved. In addition to
240 mg fexofenadine hydrochloride, 10 mg montelu-
kast, 750 mg tranexamic acid and 0.75 mg betametha-
zone, CsA was undertaken at a dose of 2.5 mgkg per
day. After a week, she showed an apparent improve-
ment in her itching, but, suffered from epigastric dis-
tress after taking CsA. We therefore tapered the dose
to 0.9 mgkg per day and the epigastric distress was
improved, but her itching did not worsen. After the
start of CsA, we tapered a dose of betamethazone and
eventually discontinued 19 months later. When we ta-
pered the dose of CsA to 0.5 mgkg per day after
nine months treatment, her itching worsened. We
then returned the dose to 0.9 mgkg per day and
have continued this treatment for 32 months. At this
stage, rubbing her skin with 60 gmm2 pressure did
not develop wheal and itching, but flare in the area
smaller than that before the treatment with CsA.
CASE 4
A 26-year-old woman had a six-month history of
wheals and itching. Despite treatment with H1-
antagonists, leukotriene antagonists and corticoster-
oids her symptoms had not improved. She developed
wheals even when she took a shower because of the
water pressure. In addition to 10 mg bepotastine, 40
mg homochlorcyclizine, CsA was administered at a
dose of 2.7 mgkg per day. After two weeks, she felt a
slight improvement in her itching. After one month,
she recognized further improvement of the itching
and a reduction of wheal frequency. She continued to
take CsA for eight months without apparent side ef-
fects. In spite of clinical improvement, no apparent
change was observed in skin reactions, exept for itch-
ing upon rubbing with 60 gmm2 pressure.
CASE 5
A 65-year-old woman had a 15-year history of wheals.
Despite treatment with H1-antagonists and corti-
costeroids, her symptoms had never improved. She
took CsA at a dose of 2.0 mgkg per day in addition
to 40 mg homochlorcyclizine, 10 mg loratadine and
50 mg hydroxyzine pamonate. We discontinued it two
weeks later, because her symptoms had not im-
proved at all during this period and she did not hope
to increase the dose of CsA. No apparent side effects
were observed during the treatment with CsA.
CASE 6
A 43-year-old man had a five-year history of wheals.
Despite treatment with H1-antagonists and leukot-
riene antagonists, his symptoms had not improved.
We administered CsA at a dose of 0.8 mgkg per day
in addition to 20 mg cetirizine hydrochloride, 10 mg
montelukast and 1500 mg tranexamic acid. We dis-
continued CsA a week later because of a headache
and nausea. His symptoms did not improve during
this period.
DISCUSSION
We treated six patients with antihistamine-resistant
DU with oral CsA. Both wheals and itching in four pa-
tients were improved by 2.5-3.4 mgkgday CsA
added to other preceding medications without severe
adverse effects. One of them developed epigastric
distress at a dose of 2.5 mgkgday, but it disap-
peared at a dose of 0.9 mgkgday. Other common
side effects of CsA, such as renal dysfunction and hy-
pertension, were not observed in all cases in this re-
port. The common clinical feature in the four effective
cases was severe itching that appeared before appar-
ent wheal development. The time from the com-
mencement of CsA treatment to the first recognition
of improvement was two days, two weeks, one week
and two weeks, respectively. Hyper-sensitivities of
skin for mechanical stimuli were not completely abol-
ished by the treatment except for Case 1. However,
the degrees and frequencies of wheal development
were satisfactorily improved together with incidence
of scratching for eight months or longer. Moreover,
corticosteroids used in Case 3 was successfully dis-
continued during the treatment with CsA.
Two patients, Cases 5 and 6, did not show an appar-
ent improvement of clinical symptoms. The patient in
Case 5 received only 2.0 mgkgday CsA for two
weeks, and the other one in Case 6 received as low as
0.8 mgkgday CsA for one week and stopped it be-
cause of headache and nausea. In general, a dose of
2.5 to 5.0 mgkgday CsA is used for other skin dis-
eases, such as psoriasis, atopic dermatitis, and
chronic spontaneous urticaria. Therefore, ineffective-
ness in these two cases may be due to a shortage of
CsA administration in either dose andor period.
General treatment for DU is an avoidance of me-
chanical stimuli and administration of safe and effec-
tive medications. However, in cases with severely
high sensitivity against stimuli, any conventional
medication is not effective and patients may develop
symptoms by essential daily life activities, such as
clothing, face washing and even by touching their
own hair. Moreover, patients may suffer from itching
even without apparent scratching, probably because
of the extremely reduced threshold for skin reac-
tions.
H1-receptor antagonists are a mainstay in the treat-
ment for DU.11,12 But they usually do not abolish
symptoms as they do for many cases of chronic spon-
taneous urticaria. The effect of several other treat-
ments, including H2-receptor antagonist,5 narrow-
band UVB,6 calcium antagonist,13 and anti-immuno-
globulin E14 have been reported. The combination of
Toda S et al.
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H1 and H2-antagonist may increase the threshold to
induce wheals, but could not inhibit spontaneous itch-
ing.5 Although narrow-band UVB showed high effi-
cacy and few adverse effects,6 it is not practical for
many patients who are young adults, because of the
necessity for frequent hospital visits. No significant
difference was found between a calcium antagonist
and placebo in double-blind cross-over trials.13 Anti-
immunoglobulin E appears to have great potential for
the treatment of various types of urticaria, but only
one case report with DU has been published very re-
cently.14 In general, remission rates for urticaria be-
come lower, the longer they persist for, especially
when this is beyond a year from the onset. However,
three patients in this report showed an improvement
in two weeks, after the treatment course, of 4, 5 and
12 years respectively. Moreover, all symptoms of the
patient with a four years history had completely dis-
appeared after the treatment with CsA for 21 months
(Case 1).
The mechanism of CsA, which inhibits functions of
T-cells, to improve DU is a matter of discussion. CsA,
but not corticosteroid, inhibits the release of hista-
mine from human mast cells15 and basophils16 in vi-
tro. On the other hand, Grattan et al. have reported
that treatment of chronic idiopathic urticaria with
CsA did not change the degrees of skin reactions
against preserved autologous serum, in spite of clini-
cal improvement, suggesting that CsA had no effect
on the releasability of skin mast cells.17 Moreover, no
additional effect on wheal and flare formation, in-
duced by mechanical stimuli under the treatment
with anti-histamines, was observed in Case 4 by the
treatment of CsA in spite of the remission of itching.
Alternatively, CsA may either inhibit production of
certain IgE, which could be passively transferred
from sera of patients with DU18 or vaso-neurological
activities of the skin via a mechanism that has not yet
been recognized by us.
Regarding the period of treatment, many patients
with chronic spontaneous urticaria treated with CsA
for one to three months relapsed after stopping it. Re-
cently, Kessel and Toubi have reported that pro-
longed treatment with CsA may reduce the risk of re-
lapse in chronic urticaria.19 In our cases, two of three
patients who took tapering of CsA had relapsed after
two- and nine-months treatments (Case 2 and 3).
However, in Case 2, the second trial of tapering after
seven months treatment from the first trial did not
cause a recurrence. Therefore, sufficient treatment
with CsA in both amount and period may be impor-
tant for prolonged control and possibly for the cure of
DU.
In conclusion, CsA may be worth trying for
antihistamine-resistant DU, especially in those patient
cases characterized by severe itching. Further stud-
ies on a larger scale are expected to be conducted in
order to generate stronger levels of clinical evidence.
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